Combination Chemotherapy with Etoposide, Doxorubicin, Cisplatin (EAP) for Recurred or Metastatic Gastric.
- Author:
Nam Kuk CHO
1
;
Tae Sik CHOI
;
Yeon Hee PARK
;
Seung Chul LEE
;
Young Jin YUH
;
Sung Rok KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Stomach neoplasm;
Etoposide;
Doxorubicin;
Cisplatin;
Chemotherapy
- MeSH:
Cisplatin*;
Doxorubicin*;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide*;
Fluorouracil;
Humans;
Stomach Neoplasms
- From:Journal of the Korean Cancer Association
2000;32(3):524-530
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We performed this study to evaluate the efficacy and the safety of EAP regimen as a second line therapy for the recurred or metastatic gastric cancer unresponsive to 5-fluorouracil based chemotherapy. MATERIALS AND METHODS: Recurred or metastatic gastric cancer patients unresponsive to 5- fluorouracil based regimen were entered into this trial. They were treated by EAP chemotherpy which consisted of etoposide 40 mg/m2, doxorubicin 15 mg/m2 and cisplatin 25 mg/m2 IV during 3 days each every 3 weeks. RESULTS: From December 1994 to March 1998, Eighteen patients were enrolled in this protdegrees Col. Fourteen patients were evaluable for response. The overall response rate was 28.6% (95% CI: 11.7~56.7%). The median response duration was 21 weeks. The median survival for all enrolled patients was 28 weeks. The major toxicity was myelosuppression. Among total of 69 cycle che motherapy, WHO grade 3 or 4 granuldegrees Cytopenia and thrombdegrees Cytopenia were observed in 71.0% and 27.5%, respectively. CONCLUSION: Second line therapy with EAP regimen was active for gastric cancer. Chemotherapy induced toxicities were moderate to severe.
